AASLD 2024 guidance on ACLF and critically ill cirrhosis patients

Who it applies to

Adults with cirrhosis who develop acute decompensation or ACLF, particularly those requiring or at risk of requiring intensive care unit level support.

Key recommendations

• ACLF should be recognized as a distinct syndrome characterized by acute decompensation of cirrhosis with organ failure(s) and high short-term mortality, distinct from simple decompensated cirrhosis.
• Organ failure should be systematically assessed using standardized criteria covering liver, kidney, brain, coagulation, circulatory, and respiratory systems.
• Common precipitants such as bacterial infection, variceal hemorrhage, and alcohol-associated hepatitis should be actively sought and treated promptly since they drive the development and progression of ACLF.
• Patients with cirrhosis and sepsis or septic shock should receive early broad-spectrum antimicrobial therapy and hemodynamic support following general critical care principles, adapted to the physiology of advanced liver disease.
• Renal replacement therapy should be considered in patients with ACLF and severe acute kidney injury or hepatorenal syndrome not responding to vasoconstrictor and albumin therapy, particularly when transplantation is anticipated.
• Early and ongoing assessment for liver transplantation candidacy is recommended in patients with ACLF, since transplantation can offer survival benefit even in patients with multiple organ failures.
• A low threshold for ICU admission and multidisciplinary critical care involvement is advised given the rapid potential for multiorgan deterioration in ACLF.
• Nutritional support and avoidance of unnecessary sedation or hepatotoxic exposures are recommended as part of supportive ICU care in cirrhotic patients.
• Prognostic scoring tools incorporating number and type of organ failures should be used serially to guide goals-of-care discussions and transplant urgency rather than a single static assessment.

What is new in this edition

• Consolidation of ACLF as a formally recognized clinical entity within North American practice guidance, building on prior international (CANONIC/APASL) definitions
• Greater emphasis on structured ICU management pathways specifically tailored to cirrhotic physiology

Practice points for students

• ACLF is defined by organ failure(s) superimposed on decompensated cirrhosis, not simply by a lab value threshold.
• Always search for and treat a precipitant (infection, GI bleed, alcohol-associated hepatitis) when ACLF is suspected.
• Do not assume futility in multiorgan failure, early transplant evaluation changes outcomes.
• Serial reassessment of organ failure status matters more than a single admission score for prognosis and triage.

Condition

Other guidelines on this topic

• ACG Clinical Guideline: Preventive Care for Patients With CirrhosisACG2026Official guideline
• Cirrhosis in over 16s: assessment and management (NG50)NICE2023Summary
• EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosisEASL2018Summary

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by AASLD. It is not medical advice: always read the original guideline before applying it to patients.